Immune Monitor - July 2018

A Message from the President 

Dear Colleagues,

Let me begin by congratulating everyone who contributed to the exciting achievement of the Journal for ImmunoTherapy of Cancer (JITC), the Society for Immunotherapy of Cancer's (SITC) open access, peer-reviewed online journal, on its first impact factor of 8.374!

As many of you know, an impact factor – a calculation of the number of citations a publication's articles received in a year by the total number of articles published – quickly communicates to prospective authors the reach and quality of research a publication possesses. The JITC impact factor is the next big step toward an even brighter future for our society's online publication. 

Much of the credit goes to JITC Editor-in-Chief Pedro J. Romero, MD, and the many SITC member experts who serve as section editors and reviewers on the journals' Editorial Board. However, JITC would not be what it is today – or further, what it is becoming – without the contributions from the many authors who have submitted their field-changing research to JITC.

Now, five years after our society's launch of JITC, this achievement provides significant validation to the journal as a premier destination for cancer immunotherapy research. I encourage all prospective authors in our field to submit to JITC when considering a venue for your work.

Among the most valuable of JITC's publications are the consensus statements submitted as part of the SITC Cancer Immunotherapy Guidelines. These immunotherapy treatment recommendations play a critical role in educating oncologists and other members of the patient care team on current standards involving U.S. Food and Drug Administration-approved cancer immunotherapy treatments for a growing list of disease states. SITC expanded its Cancer Immunotherapy Guidelines offerings in May when it updated its recommendations on cutaneous melanoma. A manuscript on non-small cell lung cancer is slated to publish in JITC next month.

We're also disseminating these guidelines broadly to increase access. This includes a new, interactive series of SITC Cancer Immunotherapy Guidelines Webinars. These live events will take place approximately two months after manuscript publication and will allow authors to go further in-depth about the treatment recommendations, answer questions and discuss any late-breaking advances in the field since publication.

The first SITC Cancer Immunotherapy Guidelines Webinar will take place Monday, July 30, 6–7 p.m. EDT, focusing on the recent update of the guidelines for cutaneous melanoma. Click here to register for this free opportunity.

The need for ongoing education for clinicians about the latest advancements in immunotherapy for cancer has never been greater. At the American Society of Clinical Oncology's (ASCO) 2018 Annual Meeting, SITC staff fielded numerous questions from attendees, and served as a resource to many visitors of our society's booth at ASCO 2018. If you would like to review highlights of the meeting, SITC published daily scientific reports from the ASCO Annual Meeting, log in to your SITC CONNECT account to access our staff reports from each day of the meeting.In closing, as you enjoy a little lull in your scientific activities over the summer, and write up the results of your recent studies, I hope you will send those data to JITC, where the new 8.374 impact factor will assure great exposure to your colleagues.



Lisa H. Butterfield, PhD

SITC President


6 p.m. EDT on Monday, July 30


33rd Annual Meeting Abstract Submission 

Immune Escape Program Presentation Application


Sept. 6, 2018 in Madison, Wis.

Sept. 27, 2018 in Boston, Mass.


33rd Annual Meeting & Pre-Conference Programs


Join SITC Today!

Renew Your Membership

Journal for ImmunoTherapy of Cancer Earns First Impact Factor of 8.374

On June 26, 2018, the Journal for ImmunoTherapy of Cancer (JITC), the society's open access, peer-reviewed online journal, earned its first impact factor of 8.374. JITC's impact factor ranks in the top 8 percent of all journals published in the categories of oncology and immunology.

This accomplishment for the journal first launched in 2013 is substantial as the impact factor is a calculation of a publication’s article references over a two-year period. The JITC impact factor considered citations of articles published in the journal during 2015 and 2016. The following is a list of the 10 most-referenced JITC articles from those years:

  1. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
  2. Novel technologies and emerging biomarkers for personalized cancer immunotherapy
  3. Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
  4. Pembrolizumab
  5. Combination immunotherapy with anti-CTLA-4 and anti-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
  6. Current clinical trials testing the combination of immunotherapy with radiotherapy
  7. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
  8. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study
  9. Targeting the indoleamine 2,3-dioxygenase pathway in cancer
  10. PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?

JITC publishes on a variety of article types, including case reports, research articles and reviews. Click here to learn more about JITC submission guidelines. One article per SITC member is eligible for waived article processing charges through 2018. Submit to JITC today or become a SITC member to take advantage of this $2,400 value.

SITC Launches New Webinar Series for its Cancer Immunotherapy Guidelinesf

To supplement the expert recommendations and guidance offered in each of its Cancer Immunotherapy Guidelines, SITC will host live webinars for clinicians of all backgrounds to engage with leading experts on the most recently published consensus statement.

Beginning July 30 at 6 p.m. EDT with the recently updated SITC Cancer Immunotherapy Guidelines manuscript on cutaneous melanoma, these webinars will allow experts to further explain aspects of the manuscript, answer questions and provide updates on any recent advances in the field.

Click here to register for the free upcoming webinar on the cutaneous melanoma guideline. Future webinars will take place about two months after guidelines publications.

Daily Scientific Highlights from ASCO 2018 Available on SITC CONNECT

SITC published daily scientific highlights from the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) of presentations that focused on cancer immunotherapy.

These highlights are available on the SITC website, accessible with a free SITC CONNECT account, at the following links: